Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Among transgender men, this study reported a case of breast cancer found incidentally after a gender-affirming mastectomy, despite common lower breast cancer risks in this population, highlighting the importance of cancer screening and careful consideration of hormone therapy management in transgender and gender-diverse individuals.

This study reviewed treatments for chemotherapy-induced hair loss, finding that scalp cooling is FDA-approved for prevention, while minoxidil and bimatoprost may aid post-chemotherapy regrowth. The authors emphasized tailored therapies and the potential utility of tools like trichoscopy and trichogram.

This article discusses safety, management, and adverse effects of chemotherapy in gynecological malignancies without reporting new clinical data, and emphasizes the importance of thorough patient and drug selection.

In this study, researchers evaluated hair follicle transplantation techniques and reported that challenges such as limited follicle supply and low follicle survival rates often limit patient satisfaction, but advances in regenerative medicine may offer promising new solutions.

In this case report, a 17-year-old female with symptoms such as vaginal bleeding and weight loss was diagnosed with B-cell acute lymphoblastic leukemia, emphasizing the importance of considering hematological malignancies in young patients with unusual presentations, as early diagnosis can significantly improve outcomes.

This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.

This study demonstrated that high doses of L-cystine and vitamin B6 effectively prevent doxorubicin-induced hair loss in mice.

This review describes the variety of mucocutaneous side effects caused by antineoplastic chemotherapy, with emphasis on skin, nails, and mucous membranes, while highlighting potential severity and the possibility of needing to adjust or interrupt treatment in rare cases; it presents no new clinical results.

This study observed early cardiac effects in young minipigs following high-dose doxorubicin chemotherapy, with a decrease in heart function and changes in cardiac MRI measurements compared to controls.

This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

The researchers reported that dermatological side effects from chemotherapy for women's cancers are common and significantly affect quality of life.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

This study found that hair content of iron and zinc does not play a role in chemotherapy-induced alopecia in children with cancer.

In this study, the combination of scalp cooling therapy and a scalp lotion containing DHL-HisZnNa demonstrated a 91.3% hair recovery rate among breast cancer patients undergoing certain chemotherapy regimens, with no serious adverse events reported.

This narrative systematic review reports that gel-based, cryogel, and silicone-based cooling caps offer cost-effective and environmentally sustainable alternatives to traditional machine-operated systems for preventing chemotherapy-induced hair loss, particularly benefiting low-income and low-resource settings.

In this study, CHOP chemotherapy for intermediate grade Non-Hodgkin's Lymphoma showed predictable toxicities but was generally well tolerated without treatment interruption among most patients.

This review discusses interventions for chemotherapy-induced hair loss and reports no new clinical results; scalp cooling and nutritional support are considered potential strategies but not yet substantiated.

This article discusses the range of skin-related side effects caused by chemotherapy and radiotherapy, including novel patterns emerging with targeted therapies, but does not report new clinical results.

This study observed that 21.6% of oncology patients experienced dermatological side effects from anti-cancer drugs, with hair loss and skin pigmentation changes being the most common.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

This guideline reviews the diagnosis and treatment of malignant cutaneous angiosarcomas, highlighting the complexity of treatment and the importance of early detection despite non-specific clinical presentations.

This study found that securinine and ajmaline significantly inhibited hepatocellular carcinoma cell viability and induced apoptosis, with securinine showing lower toxicity to normal liver cells.

This study reports that permanent and severe alopecia is a newly identified complication of the FEC 100–docetaxel regimen used for adjuvant breast cancer treatment.

This review discusses the incidence, reversibility, and impact of chemotherapy-induced alopecia and concludes that scalp cooling is the most effective prevention method in most cases, though some questions remain.

This source reports that scalp cooling is currently the only safe and FDA-cleared method to potentially reduce chemotherapy-induced hair loss, with about a 50% chance of maintaining sufficient hair to avoid needing a wig.

In patients undergoing treatment with capecitabine for colon cancer and metastatic breast cancer, this study observed that hand-foot syndrome occurred more frequently than with intravenous 5-FU, but other side effects were less common.

This review discusses chemotherapy-induced alopecia, highlighting its pathogenesis, clinical patterns, and current therapeutic approaches, with no new clinical results reported.

This study found that inhibiting EGFR signaling in mice can prevent alopecia caused by cyclophosphamide treatment, highlighting its potential role in managing chemotherapy-induced hair loss.

This study reports that polyphenols from Annurca apples may safely promote hair growth and protect against chemotherapy-induced alopecia without interfering with chemotherapy regimens.